Dew, disagree. I don't think HB dumbs it down for folks like you or anyone on the board, here or over at BV, or certainly anybody in the business.
I think he recognizes there are alot of biotech investors/investment managers, some of whom were in that audience or on the web call, whose knowledge is more likely swayed by some of the misleading headlines out there that while correct, antipodally evoke the incorrect inference, e.g. the number of deaths in the trial, the (lower) AR %'s., etc. I see it as a way to address durability to the less savvy, not pumping to anyone. Those in the know don't need to be pumped. Those not so informed need to be taught what to focus on, even in the simplest of ways.
To serious biotech investors like you, I could see why you think it is pumping. To the less savvy, it's information.
News 
Market Data 
Discover 
